Literature DB >> 16353168

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

Fiamma Buttitta1, Lara Felicioni, Fabio Barassi, Carla Martella, Diego Paolizzi, Giuseppina Fresu, Simona Salvatore, Franco Cuccurullo, Andrea Mezzetti, Daniela Campani, Antonio Marchetti.   

Abstract

Mutations in the PIK3CA gene have recently been reported in different human neoplasms, including breast cancer. This paper reports the results of a systematic analysis of PIK3CA mutations in different histological types of breast carcinoma. One hundred and eighty invasive breast carcinomas, comprising 74 ductal, 56 lobular, 22 mucinous, 20 medullary, and eight papillary, were selected on the basis of their histological type in a consecutive series of 780 breast cancers. Exons 1-20 of the PIK3CA gene were subjected to SSCP analysis followed by direct sequencing. PIK3CA mutations were observed in 46 (26%) of the 180 tumours examined: 23 (50%) mutations were located in exon 9, and 23 (50%) in exon 20. Mutations were frequent in lobular (46%), less frequent in ductal (22%), and uncommon in medullary (10%), mucinous (5%), and papillary tumours (12%) (p = 0.0002). Mutations in exon 9 were more frequent in lobular carcinomas (30% of cases) than in the other histological types (less than 5% of cases) (p = 0.00014). No significant differences were observed in the distribution of mutations in exon 20. There was no significant correlation between PIK3CA mutations and other clinicopathological and biological variables, including age, tumour size, lymph node metastases, oestrogen receptor (ER) status, progesterone receptor (PgR) status, p53 gene mutations, and p53 protein expression. The findings indicate that in invasive breast carcinomas, PIK3CA alterations are mainly present in lobular and ductal tumours, whereas the other histological types, known to be associated with a favourable prognosis, show a very low incidence of PIK3CA mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353168     DOI: 10.1002/path.1908

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  37 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Authors:  Lucia Veronica Cuorvo; Paolo Verderio; Chiara Maura Ciniselli; Salvatore Girlando; Nicola Decarli; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Claudio Eccher; Chiara Cantaloni; Francesco Mauri; Michael Seckl; Marco Volante; Fiamma Buttitta; Antonio Marchetti; Quattrone Silvia; Enzo Galligioni; Paolo Dalla Palma; Mattia Barbareschi
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

4.  ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.

Authors:  Rebecca S Cook; Joan T Garrett; Violeta Sánchez; Jamie C Stanford; Christian Young; Anindita Chakrabarty; Cammie Rinehart; Yixian Zhang; Yaming Wu; Lee Greenberger; Ivan D Horak; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

5.  PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

Authors:  Mattia Barbareschi; Lucia Veronica Cuorvo; Salvatore Girlando; Emma Bragantini; Claudio Eccher; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Chiara Cantaloni; Nicola Decarli; Enzo Galligioni; Paolo Dalla Palma
Journal:  Virchows Arch       Date:  2012-06-29       Impact factor: 4.064

Review 6.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

7.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Authors:  Huan Pang; Rory Flinn; Antonia Patsialou; Jeffrey Wyckoff; Evanthia T Roussos; Haiyan Wu; Maria Pozzuto; Sumanta Goswami; John S Condeelis; Anne R Bresnick; Jeffrey E Segall; Jonathan M Backer
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

8.  Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Authors:  Magdalena Bieniasz; Parvathi Radhakrishnan; Najme Faham; Jean-Paul De La O; Alana L Welm
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

9.  Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

Authors:  Enrique Lerma; Lluis Catasus; Alberto Gallardo; Gloria Peiro; Carmen Alonso; Ignacio Aranda; Agusti Barnadas; Jaime Prat
Journal:  Virchows Arch       Date:  2008-08-05       Impact factor: 4.064

10.  Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Authors:  Sjors M Kas; Julian R de Ruiter; Koen Schipper; Stefano Annunziato; Eva Schut; Sjoerd Klarenbeek; Anne Paulien Drenth; Eline van der Burg; Christiaan Klijn; Jelle J Ten Hoeve; David J Adams; Marco J Koudijs; Jelle Wesseling; Micha Nethe; Lodewyk F A Wessels; Jos Jonkers
Journal:  Nat Genet       Date:  2017-06-26       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.